Towards harmonization of solutions used for cystic fibrosis diagnosis by nasal potential difference measurements: A formulation approach with CHESS® software.

Chemical equilibrium Cystic fibrosis Différence de potentiel transépithélial Nasal Formulation Modeling Modélisation Mucoviscidose Nasal transepithelial potential difference Stability Stabilité Équilibre chimique

Journal

Annales pharmaceutiques francaises
ISSN: 0003-4509
Titre abrégé: Ann Pharm Fr
Pays: France
ID NLM: 2985176R

Informations de publication

Date de publication:
Jan 2022
Historique:
received: 23 12 2020
revised: 04 05 2021
accepted: 06 05 2021
pubmed: 17 5 2021
medline: 29 12 2021
entrez: 16 5 2021
Statut: ppublish

Résumé

One diagnosis of cystic fibrosis involves measuring the nasal transepithelial potential difference (NPD) as a complementary technique in the forms of the disease, where the sweat test is non-discriminating. The NPD is measured using solutions with and without chlorides, containing a variety of substances whose activities on nasal mucus membranes are studied or assessed. Among the solutions described in the literature and used in specialized centers, none seems to be best adapted for industrial production for reasons of stability (formulas of the international consensus of Rowe et al. and formulas of Knowles et al.) and/or potential toxicity (formulas of Middleton et al.). Defining new formulas, according to those of the international consensus, with greater physicochemical and microbiological stability. The reformulation tests were conducted on the formulas of Rowe et al., using CHESS® (CHemical Equilibrium of Species and Surfaces) software for modeling aqueous systems that substantially reduced the number of experiments. CHESS® software was first validated using models of ideal and non-ideal solutions. Thereafter, experimentation was carried out for the sake of comparison with theoretical data. CHESS® software using models of ideal and non-ideal solutions were validated. The experimentation confirmed the theoretical data, and new formulas were assessed based on their physicochemical (pH, content, Osmolality) and microbiological stability. The new formulas defined here guarantee excellent physicochemical and microbiological stability of diagnostic solutions, indispensable criteria for harmonizing and comparing results from different specialized centers using NPD measurements. These new formulas apply to the harmonization approach of techniques for measuring the nasal transepithelial potential difference.

Sections du résumé

BACKGROUND BACKGROUND
One diagnosis of cystic fibrosis involves measuring the nasal transepithelial potential difference (NPD) as a complementary technique in the forms of the disease, where the sweat test is non-discriminating. The NPD is measured using solutions with and without chlorides, containing a variety of substances whose activities on nasal mucus membranes are studied or assessed. Among the solutions described in the literature and used in specialized centers, none seems to be best adapted for industrial production for reasons of stability (formulas of the international consensus of Rowe et al. and formulas of Knowles et al.) and/or potential toxicity (formulas of Middleton et al.).
OBJECTIVE(S) OBJECTIVE
Defining new formulas, according to those of the international consensus, with greater physicochemical and microbiological stability.
METHODS METHODS
The reformulation tests were conducted on the formulas of Rowe et al., using CHESS® (CHemical Equilibrium of Species and Surfaces) software for modeling aqueous systems that substantially reduced the number of experiments. CHESS® software was first validated using models of ideal and non-ideal solutions. Thereafter, experimentation was carried out for the sake of comparison with theoretical data.
RESULTS RESULTS
CHESS® software using models of ideal and non-ideal solutions were validated. The experimentation confirmed the theoretical data, and new formulas were assessed based on their physicochemical (pH, content, Osmolality) and microbiological stability.
CONCLUSION CONCLUSIONS
The new formulas defined here guarantee excellent physicochemical and microbiological stability of diagnostic solutions, indispensable criteria for harmonizing and comparing results from different specialized centers using NPD measurements. These new formulas apply to the harmonization approach of techniques for measuring the nasal transepithelial potential difference.

Identifiants

pubmed: 33992643
pii: S0003-4509(21)00071-7
doi: 10.1016/j.pharma.2021.05.002
pii:
doi:

Substances chimiques

Cystic Fibrosis Transmembrane Conductance Regulator 126880-72-6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

26-34

Informations de copyright

Copyright © 2021 Académie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.

Auteurs

H Sadou Yayé (H)

Sorbonne Université, AP-HP, Hôpital Pitié Salpêtrière, Service de Pharmacie, 47-83, boulevard de l'Hôpital, 75013 Paris, France; Université Paris-Saclay, UFR de Pharmacie, Laboratoire Matériaux et Santé, EA 401, 92296, Châtenay-Malabry, France. Electronic address: hassane.sadou-yaye@aphp.fr.

E Caudron (E)

Université Paris-Saclay, Lipides, Systèmes Analytiques et Biologiques, 92296, Châtenay-Malabry, France; Service de Pharmacie, Hôpital Européen Georges Pompidou, APHP, Centre Université-Paris, 20, rue Leblanc, 75015, Paris, France.

I Sermet-Gaudelus (I)

INSERM U 1151, Institut Necker Enfants Malades, Paris, France.

I Nicolis (I)

UR 7537 BioSTM, Université de Paris, UFR de Pharmacie, 4 avenue de l'Observatoire, Paris, France. Electronic address: ioannis.nicolis@u-paris.fr.

P Prognon (P)

Université Paris-Saclay, Lipides, Systèmes Analytiques et Biologiques, 92296, Châtenay-Malabry, France; Service de Pharmacie, Hôpital Européen Georges Pompidou, APHP, Centre Université-Paris, 20, rue Leblanc, 75015, Paris, France.

D Pradeau (D)

Agence Générale des Équipements et Produits de Santé, Département de Contrôle Qualité et Développement Analytique, AP-HP, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH